Viatris (VTRS) is a global generic and branded pharmaceutical company that has been navigating a slow but steady revenue decline since its formation in 2020, with annual sales sliding from a peak of roughly $17.9 billion in 2021 to about $14.3 billion in 2025 — a contraction driven largely by asset divestitures and pricing pressure in generics. Profitability has deteriorated sharply in recent years: operating margins have compressed toward zero or negative territory, and the most recent fiscal year produced an EBITDA of just $135 million — a fraction of the $3–4 billion levels seen in 2022–2023. On the positive side, the balance sheet carries a manageable debt load relative to equity, current ratios remain healthy above 1.5x, and capital spending is disciplined and modest relative to revenue. The big picture is a company in strategic transition, working through divestitures and restructuring while trying to stabilize its financial profile — but the near-term earnings picture is under real pressure.
Snapshot & Big Picture
Viatris was formed in November 2020 through the combination of Mylan and Pfizer's Upjohn division, creating one of the world's largest generic and off-patent branded pharmaceutical companies. The company operates across developed and emerging markets with a sprawling portfolio of thousands of medicines. Since formation, management has pursued a strategy of divesting non-core assets to pay down debt and refocus the business, which has contributed to the topline shrinkage visible in the annual data. The core challenge is that generic drug pricing remains persistently deflationary, making revenue growth difficult even as the company attempts to build out a higher-margin branded and complex products pipeline.
| Fiscal Year | Revenue | EBITDA | Gross Margin | Operating Margin |
|---|---|---|---|---|
| 2018 | $11.43B | $3.02B | 35.0% | 7.9% |
| 2019 | $11.50B | $2.73B | 33.9% | 6.2% |
| 2020 | $11.95B | $2.01B | 31.8% | -1.8% |
| 2021 | $17.89B | $4.47B | 31.2% | -0.2% |
| 2022 | $16.26B | $4.64B | 40.0% | 9.9% |
| 2023 | $15.43B | $3.51B | 41.7% | 5.0% |
| 2024 | $14.74B | $2.90B | 38.2% | 0.1% |
| 2025 | $14.30B | $135M | 35.1% | -18.6% |
Latest Quarter Snapshot
The most recent data available — for the quarter ending June 30, 2026, filed August 6, 2026 — is more current than the annual figures and provides the clearest window into where Viatris stands today. Revenue for the quarter came in at $3.76 billion, with a gross margin of 38.8%, which is a modest sequential recovery from the compressed 2025 annual gross margin of 35.1%. However, the operating margin remained nearly flat at just 0.2%, and the net margin was negative at -4.5%, indicating that below-the-operating-line items — likely interest expense and potentially restructuring charges — are still a significant drag on the bottom line. EBITDA for the quarter was $682 million, which on an annualized basis would imply roughly $2.7 billion for the full year, a meaningful step up from the dismal $135 million reported for full-year 2025 and suggesting the prior year included substantial one-time charges. The current ratio stood at 1.58x and the debt-to-equity ratio at 0.94x, both in line with recent annual trends.
| Metric | Q2 2026 (Jun 30, 2026) |
|---|---|
| Revenue | $3.76B |
| EBITDA | $682M |
| Gross Margin | 38.8% |
| Operating Margin | 0.2% |
| Net Margin | -4.5% |
| Current Ratio | 1.58x |
| Debt-to-Equity | 0.94x |
Profitability
Viatris's profitability trend over the multi-year period is a tale of two phases. From 2022 through 2023, the company posted its best gross margins in the dataset — above 40% — alongside positive operating margins of roughly 5–10%, suggesting the post-merger integration and divestiture program was bearing fruit. However, starting in 2024, the trajectory reversed sharply. Gross margin fell from 41.7% in 2023 to 35.1% in 2025, and the operating margin collapsed to -18.6% in 2025, its worst reading in the dataset. The 2025 annual EBITDA of just $135 million (compared to $3.5 billion in 2023) strongly implies the presence of large non-cash or one-time charges — such as goodwill impairments or restructuring costs — embedded in that year's results. Net margin figures were not available in the filings for the annual periods. The Q2 2026 quarterly data offers a tentative sign of stabilization, with gross margins recovering toward 39% and EBITDA rebounding, though operating and net margins remain under pressure.
Financial Health
Viatris's balance sheet has held up reasonably well through a period of operational turbulence. The current ratio has generally stayed above 1.2x across the full dataset and improved to 1.58x in the most recent quarter, suggesting adequate short-term liquidity. The debt-to-equity ratio has been declining gradually from around 1.08x in 2020 to 0.75x in 2024, though it ticked back up to 0.94x in Q2 2026 — still a manageable level for a pharmaceutical company of this scale. The company's debt reduction effort, funded in part by asset sale proceeds, has been a key priority since formation.
On capital expenditures, Viatris is notably capital-light relative to its revenue base. Annual capex has ranged from $213 million to $457 million, consistently representing only about 2–2.5% of revenue — modest for an industrial-scale pharmaceutical manufacturer. This low capital intensity suggests the company is not making heavy bets on new manufacturing infrastructure and is instead managing existing capacity carefully.
| Period | Capital Expenditures | CapEx / Revenue |
|---|---|---|
| FY 2018 | $252M | 2.2% |
| FY 2019 | $213M | 1.9% |
| FY 2020 | $243M | 2.0% |
| FY 2021 | $457M | 2.6% |
| FY 2022 | $406M | 2.5% |
| FY 2023 | $377M | 2.4% |
| FY 2024 | $326M | 2.2% |
| FY 2025 | $379M | 2.6% |
| Q2 2026 (quarterly) | $40M | 1.1% |
The Q2 2026 quarterly capex of just $40 million (1.1% of quarterly revenue) is notably low, which could reflect timing within the fiscal year rather than a structural shift. Over the multi-year trend, capex intensity has been flat-to-declining, consistent with a business that is harvesting its existing asset base rather than aggressively expanding it — a rational posture given the ongoing divestiture strategy and revenue headwinds.
Growth
Viatris's revenue growth picture is mixed and complicated by the transformative nature of its 2020 formation and subsequent divestitures, which make year-over-year comparisons inherently noisy.
| CAGR Window | Start Year | End Year | Start Revenue | End Revenue | CAGR |
|---|---|---|---|---|---|
| 3-Year | FY 2022 | FY 2025 | $16.26B | $14.30B | -4.2% |
| 5-Year | FY 2020 | FY 2025 | $11.95B | $14.30B | +3.7% |
| 10-Year | N/A | N/A | — | — | Not available — Viatris was formed in 2020 and does not have ten years of SEC filing history as a standalone company. |
The 3-year revenue CAGR of -4.2% captures the real post-peak contraction underway since 2022, driven by asset sales and generic pricing erosion. The 5-year CAGR of +3.7% looks more favorable but is partly an artifact of starting from the partial-year 2020 base when the Mylan–Upjohn combination had just closed. Taken together, these figures suggest that Viatris is a business in managed decline on the top line, with any organic revenue stabilization still a work in progress.
Leave a Comment